Academic Journal
Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.
| Title: | Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry. |
|---|---|
| Authors: | Barenbrug L; Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., van der Molen RG; Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., Maurits JSF; IQ Health Science Department, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., Seyger MMB; Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., Otero ME; Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., Gostynski AH; Department of Dermatology, Maastricht University Medical Center+, Maastricht, The Netherlands., Homan FM; Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands., Ossenkoppele PM; Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands., Haeck IM; Department of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands., Hendricksen-Roelofzen JHJ; Department of Dermatology, Streekziekenhuis Koningin Beatrix, Winterswijk, The Netherlands., Körver JEM; Department of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands., Dodemont SRP; Department of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands., Velstra B; Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands., Berends MAM; Department of Dermatology, Slingeland Ziekenhuis, Doetinchem, The Netherlands., Weppner-Parren LJMT; Department of Dermatology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, The Netherlands., Keijsers R; Department of Dermatology, Zuyderland Medisch Centrum, Sittard-Geleen/Heerlen, The Netherlands., Oostveen AM; Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands., Peters B; Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands., Mommers RJM; Department of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands., van Doorn MBA; Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands., Tjioe M; Department of Dermatology, Bravis, Bergen op Zoom, The Netherlands., Arnold PW; Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands., Kuijpers ALA; Department of Dermatology, Máxima MC, Eindhoven, The Netherlands., Kleinpenning MM; Department of Dermatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands., de Jong EMGJ; Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands., van den Reek JMPA; Department of Dermatology, Radboud University Medical Center (Radboudumc), Nijmegen, The Netherlands. |
| Source: | Journal of psoriasis and psoriatic arthritis [J Psoriasis Psoriatic Arthritis] 2025 Apr 01; Vol. 10 (3), pp. 91-100. Date of Electronic Publication: 2025 Apr 01 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: National Psoriasis Foundation Country of Publication: United States NLM ID: 101695066 Publication Model: eCollection Cited Medium: Internet ISSN: 2475-5311 (Electronic) Linking ISSN: 24755303 NLM ISO Abbreviation: J Psoriasis Psoriatic Arthritis Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Overland Park, OR] : National Psoriasis Foundation, [2015]- |
| Abstract: | Background: Drug survival of biologics for psoriasis has reported to be lower in females than males for first-generation biologics (TNF-α/interleukin (IL) 12/23 inhibitors (i)); insights for newer biologics (IL17i and IL23i) are scarce. Objectives: To study sex-differences in drug survival and other treatment outcomes of biologics (including IL17i/IL23i) in patients with psoriasis. Methods: Data were obtained from the Dutch, prospective, multicenter, BioCAPTURE registry. Kaplan-Meier drug survival curves were split for specific discontinuation reasons and stratified for sex. Cox regression models with confounder correction were used to investigate the association of sex with drug survival. Adverse events (AEs) leading to biologic discontinuation were compared between sexes. Confounder-corrected Generalized Estimated Equation models were used to compare the course Psoriasis Area and Severity Index (PASI), Treatment Satisfaction Questionnaire for Medication (TSQM)) scores, and Dermatology Life Quality Index (DLQI) scores between sexes. Results: We included 428 females and 703 males (respectively 744 and 1069 treatment episodes). For all biologics, female sex was associated with shorter overall, AE-related, and effectiveness-related drug survival. For IL17i/IL23i specifically, female sex was associated with shorter overall and effectiveness-related drug survival, but not with shorter AE-related drug survival. In the TSQM females reported to experience more often AEs and to be, in general, less satisfied than males. No sex-differences were found for PASI and DLQI during the first year of treatment. Conclusion: Biologics, including IL17i and IL23i, showed lower drug survival rates for females. This could be linked to the sex-differences we found regarding AEs and treatment satisfaction with biologics. (© The Author(s) 2025.) |
| Competing Interests: | The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Liana Barenbrug has no conflict of interest. Marieke M. B. Seyger received grants from/was involved in clinical trials from Eli Lilly and Janssen. She served as a consultant for BMS, Eli Lilly, Janssen and Novartis; fees were paid directly to the institution. Elke M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands, from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Novartis, and UCB for research on psoriasis. Has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema including AbbVie, Amgen, Almirall, Boehringer Ingelheim, BMS, Celgene, Galapagos, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, Sanofi and UCB. All funding is not personal but goes directly to the Department of Dermatology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands. Juul M.P.A. van den Reek carried out clinical trials for AbbVie, Celgene, Almirall, and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma, Novartis, UCB and Eli Lilly and reimbursement for attending or chairing a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands. Marisol E. Otero has acted as consultant for Eli Lilly. Antoni H. Gostynski is advisory board member for AbbVie, Eli Lilly, Janssen, Leo Pharma, Pfizer, Regeneron, UCB, and Sanofi; holds shares of AbbVie, Janssen, GSK, Sanofi, UCB, and Pfizer; and is speaker for Sanofi, AbbVie, and UCB. Femke M. Homan has acted as consultant and/or paid speaker for Abbvie and Leo Pharma. Inge M. Haeck is a consultant, advisory board member, and/or speaker for Sanofi Genzyme and Regeneron Pharmaceuticals, Pfizer, LEO Pharma, AbbVie, Janssen and Eli Lilly. Sharon R.P. Dodemont has attended advisory boards of Janssen, Novartis, AbbVie and BMS. Berit Velstra has acted as paid speaker for Almirall. Romy Keijsers has acted as a paid chairman for Janssen Immunology. Martijn B.A. van Doorn is or recently was a speaker and/or advisor for and/or has received research funding from Novartis, AbbVie, Almirall, LEO pharma, Sanofi, Janssen, UCB, BMS, outside the submitted work. Milan Tjioe has carried out clinical trials for Abbvie, Almirall, Eli Lilly, Incyte, Leo Pharma, Cellgene, Novartis. All trial funding is not personal but goes to the independent research fund of the department of dermatology of Bravis Hospital Bergen op Zoom, the Netherlands. Renate G. van der Molen, Jake S. F. Maurits, Paul M. Ossenkoppele, Judith. H. J. Hendricksen-Roelofzen, John E.M. Körver, Maartje A.M. Berends, Lizelotte J.M.T. Weppner-Parren, Annet M. Oostveen, Bas Peters, Roland J.M. Mommers, Peter W. Arnold, Astrid L.A. Kuijpers, and Marloes M. Kleinpenning declare that they have no conflicts of interest. |
| Contributed Indexing: | Keywords: IL17 inhibitor; IL23 inhibitor; biologics; psoriasis; sex-differences |
| Entry Date(s): | Date Created: 20250404 Date Completed: 20260401 Latest Revision: 20260401 |
| Update Code: | 20260401 |
| PubMed Central ID: | PMC11962928 |
| DOI: | 10.1177/24755303251327926 |
| PMID: | 40183107 |
| Database: | MEDLINE |
| ISSN: | 2475-5311 |
|---|---|
| DOI: | 10.1177/24755303251327926 |